Century Therapeutics, Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Century Therapeutics, Inc. has an operating margin of -2096.5%, meaning the company retains $-2096 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -6556.9% the prior year.
Century Therapeutics, Inc.'s revenue surged 194.8% year-over-year to $6.6M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Century Therapeutics, Inc. carries a low D/E ratio of 1.19, meaning only $1.19 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 67/100, indicating a strong balance sheet with room for future borrowing.
Century Therapeutics, Inc.'s current ratio of 1.50 indicates adequate short-term liquidity, earning a score of 40/100. The company can meet its near-term obligations, though with limited headroom.
While Century Therapeutics, Inc. generated -$110.1M in operating cash flow, capex of $154K consumed most of it, leaving -$110.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Century Therapeutics, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Century Therapeutics, Inc. generates $0.87 in operating cash flow (-$110.1M OCF vs -$126.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Century Therapeutics, Inc. (IPSC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Century Therapeutics, Inc. generated $6.6M in revenue in fiscal year 2024. This represents an increase of 194.8% from the prior year.
Century Therapeutics, Inc.'s EBITDA was -$124.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.5% from the prior year.
Century Therapeutics, Inc. generated -$110.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 8.0% from the prior year.
Century Therapeutics, Inc. reported -$126.6M in net income in fiscal year 2024. This represents an increase of 7.4% from the prior year.
Century Therapeutics, Inc. earned $-1.61 per diluted share (EPS) in fiscal year 2024. This represents an increase of 30.0% from the prior year.
Century Therapeutics, Inc. held $58.4M in cash against $0 in long-term debt as of fiscal year 2024.
Century Therapeutics, Inc. had 86M shares outstanding in fiscal year 2024. This represents an increase of 42.3% from the prior year.
Century Therapeutics, Inc.'s operating margin was -2096.5% in fiscal year 2024, reflecting core business profitability. This is up 4460.4 percentage points from the prior year.
Century Therapeutics, Inc.'s net profit margin was -1920.9% in fiscal year 2024, showing the share of revenue converted to profit. This is up 4194.3 percentage points from the prior year.
Century Therapeutics, Inc. invested $107.2M in research and development in fiscal year 2024. This represents an increase of 15.7% from the prior year.
Century Therapeutics, Inc. invested $154K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 98.9% from the prior year.
IPSC Income Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $109.2M+2516.6% | $4.2M+441.1% | $771K-9.8% | $855K+219.0% | $268K+81.1% | $148K+49.5% | $99K-94.2% | $1.7M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $12K-100.0% | $29.4M+7.9% | $27.2M+16.2% | $23.4M+5.0% | $22.3M-2.2% | $22.8M+0.3% | $22.7M-8.7% | $24.9M |
| SG&A Expenses | $6.8M-11.9% | $7.8M-6.6% | $8.3M-5.0% | $8.7M+1.8% | $8.6M-4.4% | $9.0M+9.2% | $8.2M-7.6% | $8.9M |
| Operating Income | -$36.1M+3.1% | -$37.3M-7.3% | -$34.8M-11.0% | -$31.3M+28.5% | -$43.8M-22.8% | -$35.6M-1.6% | -$35.1M-9.3% | -$32.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $136K-66.3% | $404K |
| Income Tax | N/A | $1.8M+7968.2% | $22K+2100.0% | $1K+100.1% | -$869K-246.8% | $592K-37.7% | $950K-21.4% | $1.2M |
| Net Income | -$34.4M+4.6% | -$36.1M-15.6% | -$31.2M-11.2% | -$28.1M+28.8% | -$39.4M-20.4% | -$32.7M+1.7% | -$33.3M-6.5% | -$31.3M |
| EPS (Diluted) | $-0.40+2.4% | $-0.41-7.9% | $-0.38+15.6% | $-0.45+31.8% | $-0.66-20.0% | $-0.55+1.8% | $-0.56-5.7% | $-0.53 |
IPSC Balance Sheet
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $244.7M-30.7% | $353.2M-15.2% | $416.4M+19.5% | $348.5M-3.4% | $360.7M-9.3% | $397.6M-4.7% | $417.2M-8.6% | $456.2M |
| Current Assets | $137.7M-29.0% | $194.1M-4.6% | $203.5M+1.8% | $199.8M+12.9% | $177.0M+1.9% | $173.7M+7.7% | $161.3M-37.0% | $255.9M |
| Cash & Equivalents | $55.5M-5.0% | $58.4M+41.0% | $41.5M-11.4% | $46.8M-1.1% | $47.3M-14.4% | $55.3M-14.2% | $64.4M-25.8% | $86.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | $4.7M-7.1% | $5.1M | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $68.4M-64.4% | $191.9M-1.3% | $194.3M+13.9% | $170.6M-3.0% | $175.9M-1.3% | $178.3M+5.1% | $169.6M-5.3% | $179.1M |
| Current Liabilities | $22.0M-83.0% | $129.8M+577.3% | $19.2M+19.3% | $16.1M-10.0% | $17.8M-12.7% | $20.4M+6.6% | $19.2M-30.8% | $27.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $10.4M |
| Total Equity | $176.3M+9.3% | $161.4M-27.3% | $222.1M+24.9% | $177.9M-3.7% | $184.8M-15.7% | $219.2M-11.4% | $247.6M-10.7% | $277.2M |
| Retained Earnings | -$772.7M+1.2% | -$782.3M-9.4% | -$715.0M-4.6% | -$683.8M-4.3% | -$655.8M-6.4% | -$616.4M-5.6% | -$583.7M-6.0% | -$550.4M |
IPSC Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$25.6M-5.6% | -$24.2M+11.4% | -$27.3M+9.6% | -$30.2M-15.3% | -$26.2M-92.2% | -$13.6M+29.1% | -$19.3M+34.1% | -$29.2M |
| Capital Expenditures | $195K | N/A | $265K-50.8% | $539K-45.0% | $980K-70.0% | $3.3M-27.4% | $4.5M-9.8% | $5.0M |
| Free Cash Flow | -$25.8M | N/A | -$27.6M+10.4% | -$30.8M-13.1% | -$27.2M-60.9% | -$16.9M+28.8% | -$23.8M+30.6% | -$34.2M |
| Investing Cash Flow | $24.7M-19.4% | $30.6M+190.4% | -$33.9M-393.4% | $11.5M-38.0% | $18.6M+341.1% | $4.2M-39.5% | $7.0M-77.7% | $31.3M |
| Financing Cash Flow | $0+100.0% | -$602K-101.1% | $56.7M+211.6% | $18.2M+5211.0% | -$356K-218.7% | $300K+103.0% | -$10.1M-2358.3% | $448K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IPSC Financial Ratios
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 68.0%+961.6pp | -893.7%+3614.1pp | -4507.8%-845.9pp | -3661.9%+12667.2pp | -16329.1%+7742.5pp | -24071.6%+11359.7pp | -35431.3%-33566.1pp | -1865.2% |
| Net Margin | 70.1%+934.7pp | -864.6%+3183.0pp | -4047.6%-765.5pp | -3282.1%+11418.6pp | -14700.8%+7407.4pp | -22108.1%+11519.2pp | -33627.3%-31809.6pp | -1817.7% |
| Return on Equity | 31.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -14.1%-3.9pp | -10.2%-2.7pp | -7.5%+0.6pp | -8.1%+2.9pp | -10.9%-2.7pp | -8.2%-0.3pp | -8.0%-1.1pp | -6.9% |
| Current Ratio | 6.25+4.8 | 1.50-9.1 | 10.62-1.8 | 12.44+2.5 | 9.92+1.4 | 8.50+0.1 | 8.42-0.8 | 9.24 |
| Debt-to-Equity | 0.39-0.8 | 1.19+0.3 | 0.88-0.1 | 0.960.0 | 0.95+0.1 | 0.81+0.1 | 0.69+0.6 | 0.04 |
| FCF Margin | -32.1% | N/A | -3579.4%+21.4pp | -3600.8%+6552.2pp | -10153.0%+1275.4pp | -11428.4%+12561.5pp | -23989.9%-22001.0pp | -1989.0% |
Similar Companies
Frequently Asked Questions
What is Century Therapeutics, Inc.'s annual revenue?
Century Therapeutics, Inc. (IPSC) reported $6.6M in total revenue for fiscal year 2024. This represents a 194.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Century Therapeutics, Inc.'s revenue growing?
Century Therapeutics, Inc. (IPSC) revenue grew by 194.8% year-over-year, from $2.2M to $6.6M in fiscal year 2024.
Is Century Therapeutics, Inc. profitable?
No, Century Therapeutics, Inc. (IPSC) reported a net income of -$126.6M in fiscal year 2024, with a net profit margin of -1920.9%.
What is Century Therapeutics, Inc.'s earnings per share (EPS)?
Century Therapeutics, Inc. (IPSC) reported diluted earnings per share of $-1.61 for fiscal year 2024. This represents a 30.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Century Therapeutics, Inc.'s EBITDA?
Century Therapeutics, Inc. (IPSC) had EBITDA of -$124.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Century Therapeutics, Inc.'s operating margin?
Century Therapeutics, Inc. (IPSC) had an operating margin of -2096.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Century Therapeutics, Inc.'s net profit margin?
Century Therapeutics, Inc. (IPSC) had a net profit margin of -1920.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Century Therapeutics, Inc.'s free cash flow?
Century Therapeutics, Inc. (IPSC) generated -$110.3M in free cash flow during fiscal year 2024. This represents a -8.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Century Therapeutics, Inc.'s operating cash flow?
Century Therapeutics, Inc. (IPSC) generated -$110.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Century Therapeutics, Inc.'s total assets?
Century Therapeutics, Inc. (IPSC) had $353.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Century Therapeutics, Inc.'s capital expenditures?
Century Therapeutics, Inc. (IPSC) invested $154K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Century Therapeutics, Inc. spend on research and development?
Century Therapeutics, Inc. (IPSC) invested $107.2M in research and development during fiscal year 2024.
How many shares does Century Therapeutics, Inc. have outstanding?
Century Therapeutics, Inc. (IPSC) had 86M shares outstanding as of fiscal year 2024.
What is Century Therapeutics, Inc.'s current ratio?
Century Therapeutics, Inc. (IPSC) had a current ratio of 1.50 as of fiscal year 2024, which is considered adequate.
What is Century Therapeutics, Inc.'s debt-to-equity ratio?
Century Therapeutics, Inc. (IPSC) had a debt-to-equity ratio of 1.19 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Century Therapeutics, Inc.'s return on assets (ROA)?
Century Therapeutics, Inc. (IPSC) had a return on assets of -35.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Century Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Century Therapeutics, Inc. (IPSC) had $58.4M in cash against an annual operating cash burn of $110.1M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Century Therapeutics, Inc.'s Piotroski F-Score?
Century Therapeutics, Inc. (IPSC) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Century Therapeutics, Inc.'s earnings high quality?
Century Therapeutics, Inc. (IPSC) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Century Therapeutics, Inc.?
Century Therapeutics, Inc. (IPSC) scores 41 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.